Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04287829 |
|---|---|
| Brief Title: | Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA) |
| First Submitted : | November 15, 2019 |
| First Submitted that Met QC Criteria : | February 25, 2020 |
| First Posted : | February 27, 2020 |
| Last Update Submitted that Met QC Criteria : | January 13, 2023 |
| Last Update Posted : | January 17, 2023 |